All News
Curbside Consults - May 2016
How would you manage rheumatoid arthritis patients with melanoma in situ, or high liver enzymes or interstitial lung disease? Curbside consults takes on these challenging therapeutic or safety issues with answers are based on experience, literature and guidelines.
Read Article
Scleroderma Digital Ulcers Fail to Respond to Endothelin Antagonist
Khanna and coworkers have published the results of the DUAL-1 and DUAL-2 clinical trials (sponsored by Actelion Pharmaceuticals) testing the efficacy macitentan in reducing the number of new digital ulcers in patients with systemic sclerosis.
Read Article
Moderate Alcohol Intake While on Methotrexate Appears Prudent
Research presented at the annual British Society for Rheumatology conference revealed that rheumatoid arthritis patients who drink moderately while taking methotrexate appear to be at no greater risk for liver damage than nondrinkers.
Read Article
faSScinate Study Shows Tocilizumab to be Effective in Systemic Sclerosis
The results of the faSScinate trial were published in Lancet showing that treatment with Actemra (tocilizumab) resulted in a reduction in skin thickness and an improvement in lung function in patients with systemic sclerosis (SSc).
Read Article
The RheumNow Week in Review – 6 May 2016
Watch Dr. Cush discuss the highlights from this week on RheumNow.com.
Read Article
Risk of Steroid-Induced Diabetes Quantified
Glucocorticoid (or steroid) therapy is a well-known risk factor for diabetes. But what dose, given how and for how long? Dixon and colleagues from the The University of Manchester have quantified the risk of diabetes associated with steroid use.
Read Article
FDA REMS/Safety Panel Backs Educational Requirements for Opioid Prescribers
An advisory panel to the Food and Drug Administration met May 3rd and 4th to review whether the long-acting or extended release (ER/LA) opioid REMS programs approved in 2012 have had a meaningful effect on the opioid abuse problems noted nationwide. The FDA panel voted overwhelming
Read Article
Methotrexate Yields No Added Benefit in Etanercept Treated Psoriatic Arthritis Patients
Despite a paucity of clinical trial proof, methotrexate is often advocated or mandated to treat psoriatic arthritis. A recent comparison of clinical trials outcomes fails to show any added value when MTX is given to PsA patients taking etanercept.
Read Article
A Rheumatologist's Guide to Bariatric Surgery
Obesity is epidemic in North America, affecting nearly 76 million adults. Obesity is not only a risk factor for rheumatoid arthritis and osteoarthritis, it clearly worsens pain and function in most musculoskeletal (MSK) conditions and has been shown to blunt DMARD and biologic resp
Read Article
Consensus Guideline on Drug Therapy After Osteoporotic Fractures
Silverman and a panel from the IOF Fracture Working Group reviewed the data and trials to develop guidelines for the use of osteoporosis medications after incident fractures or to treat delayed fracture healing.
Read Article
Low Adherence to Biologics in Psoriasis Patients
Doshi and colleagues have conducted a retrospective claims analysis (2009 through 2012) of psoriasis patients on Medicare to examine the use and adherence to those initiating treatment with either infliximab, etanercept, adalimumab, or ustekinumab.
Read Article
Can Rituximab Change the Course of Interstitial Lung Disease?
Like other extraarticular manifestations, rheumatoid (RA) or connective tissue disease (CTD) related interstitial lung disease (ILD) is difficult to identify early and equally challenging to treat.
Read Article
Anniversary Feature: Top 5 Most-Read Articles from 1st Year
It is important to know where you’ve been, as it will most certainly color where you are going. Hence, in honor of our 1st year anniversary, we have taken note of our most popular articles.
Read Article
RheumNow Week in Review – 22 April 2016
Watch Dr. Jack Cush cover ten highlights from this week on RheumNow.com.
Read Article
Vaccine Success is Limited in Rheumatoid Arthritis
Numerous guidelines (ACR, ACIP/CDC, ATS, NICE) all call for timely vaccinations in patients with rheumatoid arthritis (RA) and those receiving immunosuppressives or biologics.
Read Article
FDA Will Review Opioid Analgesic Use and REMS Programs for Pediatric Pain Patients
Amidst a stringent regulatory environment, and with the rising use and abuse of narcotics and increasing regulation limiting narcotic analgesic use, the FDA approved (August 2015) the use of extended-release oxycodone in children (11 to 16 years old) with severe, "around-the-clock" pain
Read Article
BeST Trial and 10-Year Outcomes of Four Treatment Strategies
Markusse and investigators from The Netherlands have reported their 10 year results of treating early rheumatoid arthritis (RA) patients using targeted treatment strategies.
Read Article
HLA-B*5801 Testing Needed in Asians and Blacks with Gout
Choi and colleagues analyzed US hospitalizations (2009–2013) to assess the frequency and racial distribution of patients hospitalized with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) related to the use of urate-lowering (ULT) therapy (predominantly allopurinol).
Read Article
RheumNow Week in Review - 15 April 2016
Video recap of highlights from this week at RheumNow.com.
Read Article
Biosimilar Reports - April 2016
Major advances in biosimilars have occurred in the last three months, beginning with the FDA Arthritis Advisory Committee voting 21-3 to approve Celltrion’s Inflectra (CT-P13) and ending with the recent approval of Inflectra (generically referred to as infliximab dyyb).
Read Article